Conference details
RNA Therapeutics 2019
Pav Solanki
psolanki@smi-online.co.uk
2078276048
Fulfilling the potential of genetic discoveries requires the development of therapeutics that can specifically modulate the expression of disease-relevant genes. RNA-based drugs and antisense nucleotides, are promising examples of a newer class of biologics. Researchers have tried to overcome the major challenges for utilising RNAs in a therapeutic context, including: intracellular delivery, stability and immunogenicity.
Bringing together industry experts, to discuss the challenges for clinical translation of RNA-based therapeutics, with an emphasis on recent advances in delivery technologies and present an overview of the applications of RNA-based drugs for modulation of gene and protein expression and genome editing
KEYNOTE SPEAKERS
• Ekkehard Leberer, Senior Director, Alliance Management, Sanofi
• Shalini Andersson, Senior Director and Head of New Modalities, AstraZeneca
• Carsten Rudolf, Chief Executive Officer, Ethris Gmbh
• Paul Agris, Founder and Director, The RNA Institute
• Marian Gindy, Executive Director, Pharmaceutical Sciences, Merck Research Labs, Merck and Co
• David Giljohan, CEO, Exicure
• Ingmar Hoerr, Founder and CEO, CureVac AG
• David Blakey, Chief Scientific Officer, MiNA Therapeutics
• André Gerber, Professor of RNA Biology, University of Surrey
• Heinrich Haas, Vice President Drug Delivery, BioNTech RNA Pharmaceuticals
• Markus Mandler, Chief Scientific Officer, Accanis Biotech
• Troels Koch, Vice President and Head of Research, RNA Therapeutics, Roche
• Hans Kistemaker, Associate Director, ProQR
HIGHLIGHTS
- Discover the clinical progress of Spherical Nucleic Acids
- Understand Sanofi’s strategies to deliver therapeutic oligonucleotides across biobarriers
- Learn from ProQR how to plan for oligonucleotide supply from personalized medicine to large scale markets
- Explore the development of small activating RNA – from bench to bedside with MiNA Therapeutics
- Gain insight into the discovery and development of self-amplifying mRNA vaccines at GSK